Loading...

We've got a brand new version of Simply Wall St! Try it out

Telix Pharmaceuticals

ASX:TLX
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
TLX
ASX
A$469M
Market Cap
  1. Home
  2. AU
  3. Pharmaceuticals & Biotech
Company description

Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia. The last earnings update was 88 days ago. More info.


Add to Portfolio Compare Print
  • Telix Pharmaceuticals has significant price volatility in the past 3 months.
TLX Share Price and Events
7 Day Returns
1.9%
ASX:TLX
4.7%
AU Biotechs
0.9%
AU Market
1 Year Returns
143%
ASX:TLX
50.9%
AU Biotechs
16.3%
AU Market
TLX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Telix Pharmaceuticals (TLX) 1.9% 15.8% 36.4% 143% - -
AU Biotechs 4.7% 8.7% 20% 50.9% 168.8% 226.4%
AU Market 0.9% 1.9% 5.1% 16.3% 22.3% 22.5%
1 Year Return vs Industry and Market
  • TLX outperformed the Biotechs industry which returned 50.9% over the past year.
  • TLX outperformed the Market in Australia which returned 16.3% over the past year.
Price Volatility
TLX
Industry
5yr Volatility vs Market

TLX Value

 Is Telix Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Telix Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is A$1.835.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Telix Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Telix Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ASX:TLX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in AUD A$-0.09
ASX:TLX Share Price ** ASX (2019-11-18) in AUD A$1.84
Global Biotechs Industry PE Ratio Median Figure of 145 Publicly-Listed Biotechs Companies 30.8x
Australia Market PE Ratio Median Figure of 519 Publicly-Listed Companies 18.63x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Telix Pharmaceuticals.

ASX:TLX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ASX:TLX Share Price ÷ EPS (both in AUD)

= 1.84 ÷ -0.09

-20.52x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Telix Pharmaceuticals is loss making, we can't compare its value to the Global Biotechs industry average.
  • Telix Pharmaceuticals is loss making, we can't compare the value of its earnings to the Australia market.
Price based on expected Growth
Does Telix Pharmaceuticals's expected growth come at a high price?
Raw Data
ASX:TLX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -20.52x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
77.7%per year
Global Biotechs Industry PEG Ratio Median Figure of 85 Publicly-Listed Biotechs Companies 1.39x
Australia Market PEG Ratio Median Figure of 347 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Telix Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Telix Pharmaceuticals's assets?
Raw Data
ASX:TLX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in AUD A$0.20
ASX:TLX Share Price * ASX (2019-11-18) in AUD A$1.84
Australia Biotechs Industry PB Ratio Median Figure of 38 Publicly-Listed Biotechs Companies 3.17x
Australia Market PB Ratio Median Figure of 1,584 Publicly-Listed Companies 1.75x
ASX:TLX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ASX:TLX Share Price ÷ Book Value per Share (both in AUD)

= 1.84 ÷ 0.20

9.28x

* Primary Listing of Telix Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Telix Pharmaceuticals is overvalued based on assets compared to the AU Biotechs industry average.
X
Value checks
We assess Telix Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Telix Pharmaceuticals has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

TLX Future Performance

 How is Telix Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
77.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Telix Pharmaceuticals expected to grow at an attractive rate?
  • Telix Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 2.3%.
Growth vs Market Checks
  • Telix Pharmaceuticals's earnings growth is expected to exceed the Australia market average.
  • Telix Pharmaceuticals's revenue growth is expected to exceed the Australia market average.
Annual Growth Rates Comparison
Raw Data
ASX:TLX Future Growth Rates Data Sources
Data Point Source Value (per year)
ASX:TLX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 77.7%
ASX:TLX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 81.6%
Australia Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 13%
Australia Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 10.3%
Australia Market Earnings Growth Rate Market Cap Weighted Average 9.7%
Australia Market Revenue Growth Rate Market Cap Weighted Average 3.7%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ASX:TLX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in AUD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ASX:TLX Future Estimates Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 36 24 1
2020-12-31 14 -16 2
2019-12-31 8 -19 2
2019-11-18
ASX:TLX Past Financials Data
Date (Data in AUD Millions) Revenue Cash Flow Net Income *
2019-06-30 2 -29 -19
2019-03-31 1 -25 -16
2018-12-31 0 -21 -14
2018-09-30 -2 -16 -12
2018-06-30 -11 -10
2018-03-31 -9 -8
2017-12-31 -6 -6
2016-12-31 0

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Telix Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • Telix Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ASX:TLX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (4 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Telix Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:TLX Future Estimates Data
Date (Data in AUD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.08 0.08 0.08 1.00
2020-12-31 -0.06 -0.04 -0.08 2.00
2019-12-31 -0.08 -0.08 -0.09 2.00
2019-11-18
ASX:TLX Past Financials Data
Date (Data in AUD Millions) EPS *
2019-06-30 -0.09
2019-03-31 -0.08
2018-12-31 -0.07
2018-09-30 -0.06
2018-06-30 -0.04
2018-03-31 -0.05
2017-12-31 -0.05
2016-12-31

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Telix Pharmaceuticals is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess Telix Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Australia market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Australia market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Telix Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

TLX Past Performance

  How has Telix Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Telix Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Telix Pharmaceuticals does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Telix Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Telix Pharmaceuticals's 1-year growth to the Global Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Telix Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Telix Pharmaceuticals Company Filings, last reported 4 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ASX:TLX Past Revenue, Cash Flow and Net Income Data
Date (Data in AUD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 2.01 -19.01 12.26 20.08
2019-03-31 1.10 -16.42 10.70 19.38
2018-12-31 0.20 -13.83 9.15 18.69
2018-09-30 -2.19 -11.91 7.96 13.66
2018-06-30 -10.00 6.77 8.63
2018-03-31 -8.19 5.16 5.80
2017-12-31 -6.38 3.54 2.98
2016-12-31 -0.04 0.02 0.01
2015-12-31 -0.13 0.05 0.06

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Telix Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Telix Pharmaceuticals has efficiently used its assets last year compared to the Global Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Telix Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Telix Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Telix Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

TLX Health

 How is Telix Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Telix Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Telix Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Telix Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Telix Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 19.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Telix Pharmaceuticals Company Filings, last reported 4 months ago.

ASX:TLX Past Debt and Equity Data
Date (Data in AUD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 43.20 1.42 10.15
2019-03-31 43.20 1.42 10.15
2018-12-31 52.90 1.73 25.77
2018-09-30 52.90 1.73 25.77
2018-06-30 44.39 0.36 42.04
2018-03-31 44.39 0.36 42.04
2017-12-31 49.29 0.35 48.76
2016-12-31
2015-12-31
  • Telix Pharmaceuticals's level of debt (3.3%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Telix Pharmaceuticals's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Telix Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Telix Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 94.3% each year.
X
Financial health checks
We assess Telix Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Telix Pharmaceuticals has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

TLX Dividends

 What is Telix Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Telix Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought A$2,000 of Telix Pharmaceuticals shares you are expected to receive A$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Telix Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Telix Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ASX:TLX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 59 Stocks 2.1%
Australia Market Average Dividend Yield Market Cap Weighted Average of 390 Stocks 4%
Australia Minimum Threshold Dividend Yield 10th Percentile 1.5%
Australia Bottom 25% Dividend Yield 25th Percentile 2.4%
Australia Top 25% Dividend Yield 75th Percentile 5.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

ASX:TLX Future Dividends Estimate Data
Date (Data in A$) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 2.00
2019-12-31 0.00 2.00
2019-11-18

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Telix Pharmaceuticals has not reported any payouts.
  • Unable to verify if Telix Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Telix Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Telix Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Telix Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Australia.
X
Income/ dividend checks
We assess Telix Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.5%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Telix Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Telix Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

TLX Management

 What is the CEO of Telix Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Behrenbruch
COMPENSATION A$380,184
AGE 44
CEO Bio

Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), MBA, DPhil (Oxon), J.D., GAICD, serves as a Director of Amplia Therapeutics Pty Ltd. (formerly known as Innate Immunotherapeutics Ltd.). Dr. Behrenbruch is a Co-Founder, Managing Director and Chief Executive Officer Telix Pharmaceuticals Limited. Dr. Behrenbruch was a Co-Founder of ImaginAb, Inc. and served as its Chief Executive Officer. He is a serial entrepreneur with a diverse background in developing and commercializing biotechnology, healthcare IT and medical devices from both the operational & executive perspective. He has 20 years of C-level leadership experience in the medical, biotechnology and healthcare IT space and has significant experience as a Director of commercial and non-profit organisations. He held positions as Chief Executive Officer and executive director include Mirada Solutions, CTI Molecular Imaging (now Siemens Healthcare), Fibron Technologies and ImaginAb, Inc. Dr. Behrenbruch has taken responsibility for establishing the initial operations and financing for ImaginAb. Dr. Behrenbruch served as Vice President at Siemens Molecular Imaging following the acquisition of Mirada Solutions and CTI Molecular Imaging, where he was responsible for advanced medical imaging research for lifesciences and clinical use. He served as Chairman of Cell Therapies Pty Ltd (a partnership with the Peter MacCallum Cancer Centre). He has been Director of Telix Pharmaceuticals Limited since January 03, 2017. since May 4, 2018. He has been Executive Director of Factor Therapeutics Limited (a/k/a, Tissue Therapies Ltd) since October 12, 2015 and served as its Executive Director its since October 12, 2015 until May 31, 2017. He was Director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd., Radius Health Ltd (now Adaptix) and the Oncidium Foundation. He serves as Chairman of the Monash Engineering and IT Foundation Board. He is a Member of the Monash Engineering Foundation Board and serves as Adjunct Professor at Monash University and RMIT University. He is a Fellow of Engineers Australia in the management and biomedical colleges and a Graduate of the Australian Institute of Company Directors. He completed an engineering degree at Monash University, a D.Phil (Ph.D) in biomedical engineering from the University of Oxford, an MBA jointly awarded by New York University, Stern, HEC Paris and the London School of Economics and a JD from the University of Melbourne.

CEO Compensation
  • Chris's compensation has increased whilst company is loss making.
  • Chris's remuneration is lower than average for companies of similar size in Australia.
Management Team Tenure

Average tenure of the Telix Pharmaceuticals management team in years:

1.2
Average Tenure
  • The average tenure for the Telix Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Chris Behrenbruch

TITLE
Co-Founder
COMPENSATION
A$380K
AGE
44

Doug Cubbin

TITLE
Chief Financial Officer
COMPENSATION
A$351K
TENURE
2.5 yrs

Andreas Kluge

TITLE
Chief Medical Advisor & Executive Director
COMPENSATION
A$158K

Gabriel Liberatore

TITLE
Group Chief Operating Officer
TENURE
0.8 yrs

David Cade

TITLE
Chief Business Officer & Head of Investor Relations
TENURE
0.1 yrs

Melanie Farris

TITLE
Head of Corporate Governance & Group Secretary

Ros Wilson

TITLE
Global Head of Drug Development
TENURE
0.1 yrs

Shintaro Nishimura

TITLE
President & COO of Telix Pharmaceuticals Japan Ltd.
TENURE
1.8 yrs

Odile Jaume

TITLE
President & COO of Telix Europe
TENURE
1.7 yrs

Bernard Lambert

TITLE
President of Telix USA
Board of Directors Tenure

Average tenure and age of the Telix Pharmaceuticals board of directors in years:

2.5
Average Tenure
55.5
Average Age
  • The average tenure for the Telix Pharmaceuticals board of directors is less than 3 years, this suggests a new board.
Board of Directors

Harry McCann

TITLE
Independent Non-Executive Chairman
COMPENSATION
A$198K
AGE
78
TENURE
2.2 yrs

Chris Behrenbruch

TITLE
Co-Founder
COMPENSATION
A$380K
AGE
44
TENURE
2.8 yrs

Andreas Kluge

TITLE
Chief Medical Advisor & Executive Director
COMPENSATION
A$158K
TENURE
2.8 yrs

Mark Nelson

TITLE
Non-Executive Director
COMPENSATION
A$144K
TENURE
2.2 yrs

Jann Skinner

TITLE
Non-Executive Director
COMPENSATION
A$43K
AGE
61
TENURE
1.4 yrs

Oliver Buck

TITLE
Non-Executive Director
COMPENSATION
A$105K
AGE
50
TENURE
2.8 yrs

Rod Hicks

TITLE
Member of the Scientific Advisory Board

Jean-François Chatal

TITLE
Member of the Scientific Advisory Board

Jason Lewis

TITLE
Member of the Scientific Advisory Board

Klaus Kopka

TITLE
Member of the Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (A$) Value (A$)
X
Management checks
We assess Telix Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Telix Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

TLX News

Simply Wall St News

Telix Pharmaceuticals Limited's (ASX:TLX) Shift From Loss To Profit

Telix Pharmaceuticals Limited's (ASX:TLX):. … Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care primarily in Australia. … In this article, I will touch on the expectations for TLX’s growth and when analysts expect the company to become profitable

Simply Wall St -

Why Telix Pharmaceuticals Limited's (ASX:TLX) Investor Composition Impacts Your Returns

This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … Private Company Ownership Another important group of owners for potential investors in TLX are private companies that hold a stake of 4.63% in TLX. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: The company's high institutional ownership makes margin of safety a very important consideration to existing investors since long bull and bear trends often emerge when these big-ticket investors see a change in long-term potential of the company.

Simply Wall St -

Analysts Expect Breakeven For Telix Pharmaceuticals Limited (ASX:TLX)

Telix Pharmaceuticals Limited's (ASX:TLX): Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care primarily in Australia. … They expect the company to post a final loss in 2019, before turning a profit of AU$880.00K in 2020. … Working backwards from analyst estimates, it turns out that they expect the company to grow 61.74% year-on-year, on average, which signals high confidence from analysts.

Simply Wall St -

Brokers' Outlook On Telix Pharmaceuticals Limited (ASX:TLX)

Telix Pharmaceuticals Limited (ASX:TLX) is a company I've been following for a while, and although it's currently trading below its fair value, I have reasons to believe it may not actually reach this figure. … TLX has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … Currently, it's trading at a fair value, with a PB ratio of 2.62x vs.

Simply Wall St -

A Look At Telix Pharmaceuticals Limited (ASX:TLX) And The Healthcare Sector

However, this rate came in below the growth rate of the Australian stock market as a whole. … In the previous year, the industry saw growth of 9.22%, beating the Australian market growth of 5.37%. … Biotech companies are typically trading at a PE of 27x, higher than the rest of the Australian stock market PE of 17x.

Simply Wall St -

TLX Company Info

Description

Telix Pharmaceuticals Limited, an oncology company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia. Its products include TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma; TLX250, which is in Phase II for the diagnosis and treatment of renal cancer; TLX250-CDx, which is in Phase III for the imaging of clear cell renal cell cancer; TLX591, which is in pre-Phase III for the treatment of metastatic castrate-resistant prostate cancer; and TLX591-CDx, which is in Phase III for the imaging of prostate cancer. The company has collaboration agreements with Radboud University, University of Nantes/ARRONAX, University of Melbourne Osaka University, Winship Cancer Institute of Emory University, Merck Healthcare KGaA, and Memorial Sloan Kettering, as well as the Institute for Radiation Sciences, Osaka University and the Department of Nuclear Medicine, and Tracer Kinetics at Osaka University Graduate School of Medicine. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.

Details
Name: Telix Pharmaceuticals Limited
TLX
Exchange: ASX
Founded: 2015
A$468,567,998
253,279,999
Website: http://www.telixpharma.com
Address: Telix Pharmaceuticals Limited
55 Flemington Road,
Suite 401,
North Melbourne,
Victoria, 3051,
Australia
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ASX TLX Ordinary Shares Australian Securities Exchange AU AUD 15. Nov 2017
OTCPK TLPP.F Ordinary Shares Pink Sheets LLC US USD 15. Nov 2017
CHIA TLX Ordinary Shares Chi-X Australia AU AUD 15. Nov 2017
Number of employees
Current staff
Staff numbers
9
Telix Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/11/18 10:44
End of day share price update: 2019/11/18 00:00
Last estimates confirmation: 2019/10/15
Last earnings filing: 2019/08/22
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.